TitleAssociate Professor
InstitutionMD Anderson
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Noll KR, Bradshaw M, Sheppard D, Wefel JS. Perioperative Neurocognitive Function in Glioma Surgery. Curr Oncol Rep. 2024 Apr 04. PMID: 38573439.
      Citations:    Fields:    
    2. Cowan BA, Olivier K, Tombal B, Wefel JS. Correction to: Treatment-Related Cognitive Impairment in Patients with Prostate Cancer: Patients' Real-World Insights for Optimizing Outcomes. Adv Ther. 2024 Apr; 41(4):1770-1773. PMID: 38378976; PMCID: PMC10960746.
      Citations:    Fields:    
    3. Wefel JS, Deshmukh S, Brown PD, Grosshans DR, Sulman EP, Cerhan JH, Mehta MP, Khuntia D, Shi W, Mishra MV, Suh JH, Laack NN, Chen Y, Curtis AA, Laba JM, Elsayed A, Thakrar A, Pugh SL, Bruner DW. Impact of Apolipoprotein E Genotype on Neurocognitive Function in Patients With Brain Metastases: An Analysis of NRG Oncology's RTOG 0614. Int J Radiat Oncol Biol Phys. 2023 Dec 13. PMID: 38101486.
      Citations: 2     Fields:    
    4. Cowan BA, Olivier K, Tombal B, Wefel JS. Treatment-Related Cognitive Impairment in Patients with Prostate Cancer: Patients' Real-World Insights for Optimizing Outcomes. Adv Ther. 2024 Feb; 41(2):476-491. PMID: 37979089; PMCID: PMC10838823.
      Citations:    Fields:    Translation:Humans
    5. Noll KR, Asman P, Tasnim I, Hall M, Connelly K, Swamy C, Ene C, Tummala S, Grasu RM, Liu HL, Kumar VA, Muir M, Prinsloo S, Michener H, Wefel JS, Ince NF, Prabhu SS. Intraoperative language mapping guided by real-time visualization of gamma band modulation electrocorticograms: Case report and proof of concept. Neurooncol Pract. 2024 Feb; 11(1):92-100. PMID: 38222047; PMCID: PMC10785572.
    6. Katlowitz KA, Beckham TH, Kudchadker RJ, Wefel J, Elamin YY, Weinberg JS. A Novel Multimodal Approach to Refractory Brain Metastases: A Case Report. Adv Radiat Oncol. 2024 Feb; 9(2):101349. PMID: 38405307; PMCID: PMC10885573.
    7. Holdhoff M, Nicholas MK, Peterson RA, Maraka S, Liu LC, Fischer JH, Wefel JS, Fan TM, Vannorsdall T, Russell M, Iacoboni M, Tarasow TM, Hergenrother PJ, Dudek AZ, Danciu OC. Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad087. PMID: 37554223; PMCID: PMC10406430.
      Citations: 1     
    8. Catalino MP, Noll KR, Wefel JS, Michener H, Prinsloo S, Tummala S, Prabhu S. Decoding the clinical effects of low-grade glioma-induced cortical excitability. J Neurosurg. 2024 Jan 01; 140(1):18-26. PMID: 37439490.
      Citations:    Fields:    Translation:Humans
    9. Altan M, Wang Y, Song J, Welsh J, Tang C, Guha-Thakurta N, Blumenschein GR, Carter BW, Wefel JS, Ghia AJ, Yeboa DN, McAleer MF, Chung C, Woodhouse KD, McGovern SL, Wang C, Kim BYS, Weinberg JS, Briere TM, Elamin YY, Cascone T, Negrao MV, Skoulidis F, Ferrarotto R, Heymach JV, Li J, Le X. Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial. J Immunother Cancer. 2023 07; 11(7). PMID: 37402581; PMCID: PMC10335483.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    10. Gondi V, Deshmukh S, Brown PD, Wefel JS, Armstrong TS, Tome WA, Gilbert MR, Konski A, Robinson CG, Bovi JA, Benzinger TLS, Roberge D, Kundapur V, Kaufman I, Shah S, Usuki KY, Baschnagel AM, Mehta MP, Kachnic LA. Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms With Hippocampal Avoidance During Whole-Brain Radiation Therapy for Brain Metastases: Final Results of NRG Oncology CC001. Int J Radiat Oncol Biol Phys. 2023 11 01; 117(3):571-580. PMID: 37150264.
      Citations: 1     Fields:    Translation:Humans
    11. Gregory TA, Mastall M, Lin H, Hess KR, Yuan Y, Martin-Bejarano Garcia M, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D, Weathers SP, Harrison RA, de Groot JF, Puduvalli VK, Penas-Prado M, Majd NK. Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad032. PMID: 37114244; PMCID: PMC10129387.
    12. Gan HK, Preusser M, Seidel C, Lombardi G, Bentsion D, Wick A, Lassman AB, Pugh SL, Wang TJC, Aldape K, Vogelbaum MA, Sulman EP, Won M, Zhang P, Moazami G, Macsai MS, Gilbert MR, Bain EE, Blot V, Ansell PJ, Samanta S, Kundu MG, Armstrong TS, Wefel JS, de Vos FY, Hsu S, Cardona AF, Peterson RA, Gedye C, Bourg V, Curran WJ, Mehta MP. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. Neuro Oncol. 2023 02 14; 25(2):339-350. PMID: 35849035; PMCID: PMC9925712.
      Citations:    Fields:    
    13. Guran E, Hu J, Wefel JS, Chung C, Cata JP. Perioperative considerations in patients with chemotherapy-induced cognitive impairment: a narrative review. Br J Anaesth. 2022 12; 129(6):909-922. PMID: 36270848.
      Citations:    Fields:    Translation:Humans
    14. Beer TM, Shore N, Morgans A, Winters-Stone K, Wefel JS, George DJ. Functional impact of androgen-targeted therapy on patients with castration-resistant prostate cancer. BJUI Compass. 2022 Nov; 3(6):424-433. PMID: 36267196; PMCID: PMC9579880.
    15. Lehrer EJ, Jones BM, Dickstein DR, Green S, Germano IM, Palmer JD, Laack N, Brown PD, Gondi V, Wefel JS, Sheehan JP, Trifiletti DM. The Cognitive Effects of Radiotherapy for Brain Metastases. Front Oncol. 2022; 12:893264. PMID: 35847842; PMCID: PMC9279690.
    16. Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, Wefel JS, Michalski JM, Angyalfi SJ, Lukka H, Faria SL, Rodrigues GB, Lee RJ, Seaward SA, Allen AM, Monitto DC, Seiferheld W, Sartor O, Feng F, Sandler HM, Martin AG, Beauchemin MC. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022 05 14; 399(10338):1886-1901. PMID: 35569466.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    17. Noll KR, Wefel J. On the classification of impairment in neuropsychological research and practice in the neuro-oncological setting. Neurooncol Pract. 2022 Aug; 9(4):255-256. PMID: 35859538; PMCID: PMC9290879.
    18. Wefel JS, Woods SP. Measuring everyday functioning in patients with brain tumor: The long rows yet to hoe. Neurooncol Pract. 2022 Aug; 9(4):253-254. PMID: 35859540; PMCID: PMC9290877.
    19. Wefel JS, Ryan CJ, Van J, Jackson JC, Morgans AK. Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors. CNS Drugs. 2022 05; 36(5):419-449. PMID: 35522374; PMCID: PMC9073450.
      Citations:    Fields:    Translation:Humans
    20. Chung C, Brown PD, Wefel JS. Lessons learned from proton vs photon radiation therapy for glioblastoma signal-finding trial. Neuro Oncol. 2022 05 04; 24(5):851. PMID: 35460425; PMCID: PMC9071287.
      Citations:    Fields:    Translation:Humans
    21. Muir M, Patel R, Traylor J, de Almeida Bastos DC, Prinsloo S, Liu HL, Noll K, Wefel J, Tummala S, Kumar V, Prabhu S. Validation of Non-invasive Language Mapping Modalities for Eloquent Tumor Resection: A Pilot Study. Front Neurosci. 2022; 16:833073. PMID: 35299624; PMCID: PMC8923233.
    22. Schagen SB, Tsvetkov AS, Compter A, Wefel JS. Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach? Nat Rev Neurol. 2022 Mar; 18(3):173-185. PMID: 35140379.
      Citations:    Fields:    Translation:Humans
    23. Parsons MW, Peters KB, Floyd SR, Brown P, Wefel JS. Preservation of neurocognitive function in the treatment of brain metastases. Neurooncol Adv. 2021 Nov; 3(Suppl 5):v96-v107. PMID: 34859237; PMCID: PMC8633744.
      Citations: 1     
    24. Wefel JS, Zhou R, Sulman EP, Boehling NS, Armstrong GN, Tsavachidis S, Liang FW, Etzel CJ, Kahalley LS, Small BJ, Scheurer ME, Bondy ML, Liu Y. Genetic modulation of longitudinal change in neurocognitive function among adult glioma patients. J Neurooncol. 2022 Jan; 156(1):185-193. PMID: 34817796.
      Citations:    Fields:    Translation:HumansCells
    25. Chung C, Brown PD, Wefel JS. Short reply to "Proton therapy for newly diagnosed glioblastoma: more room for investigation" by R. Press et al. Neuro Oncol. 2021 11 02; 23(11):1982. PMID: 34453547; PMCID: PMC8563305.
      Citations:    Fields:    Translation:Humans
    26. Noll K, King AL, Dirven L, Armstrong TS, Taphoorn MJB, Wefel JS. Neurocognition and Health-Related Quality of Life Among Patients with Brain Tumors. Hematol Oncol Clin North Am. 2022 02; 36(1):269-282. PMID: 34711455.
      Citations:    Fields:    Translation:Humans
    27. De Witt Hamer PC, Klein M, Hervey-Jumper SL, Wefel JS, Berger MS. In Reply: Functional Outcomes and Health-Related Quality of Life Following Glioma Surgery. Neurosurgery. 2021 08 16; 89(3):E189. PMID: 34131734; PMCID: PMC8364820.
      Citations:    Fields:    Translation:Humans
    28. Brown PD, Chung C, Liu DD, McAvoy S, Grosshans D, Al Feghali K, Mahajan A, Li J, McGovern SL, McAleer MF, Ghia AJ, Sulman EP, Penas-Prado M, de Groot JF, Heimberger AB, Wang J, Armstrong TS, Gilbert MR, Guha-Thakurta N, Wefel JS. A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma. Neuro Oncol. 2021 08 02; 23(8):1337-1347. PMID: 33647972; PMCID: PMC8328012.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    29. Wefel JS, Armstrong TS, Pugh SL, Gilbert MR, Wendland MM, Brachman DG, Roof KS, Brown PD, Crocker IR, Robins HI, Hunter G, Won M, Mehta MP. Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825). Neuro Oncol. 2021 07 01; 23(7):1125-1138. PMID: 33515019; PMCID: PMC8661434.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    30. Majd NK, Mastall M, Lin H, Dibaj SS, Hess KR, Yuan Y, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D, Weathers SP, Harriso RA, De Groo JF, Puduvalli VK, Penas-Prado M, Garcia MM. Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab079. PMID: 34377987; PMCID: PMC8350154.
      Citations: 1     
    31. Al Feghali KA, Randall JW, Liu DD, Wefel JS, Brown PD, Grosshans DR, McAvoy SA, Farhat MA, Li J, McGovern SL, McAleer MF, Ghia AJ, Paulino AC, Sulman EP, Penas-Prado M, Wang J, de Groot J, Heimberger AB, Armstrong TS, Gilbert MR, Mahajan A, Guha-Thakurta N, Chung C. Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessment. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab073. PMID: 34337411; PMCID: PMC8320688.
    32. Jaeckle KA, Ballman KV, van den Bent M, Giannini C, Galanis E, Brown PD, Jenkins RB, Cairncross JG, Wick W, Weller M, Aldape KD, Dixon JG, Anderson SK, Cerhan JH, Wefel JS, Klein M, Grossman SA, Schiff D, Raizer JJ, Dhermain F, Nordstrom DG, Flynn PJ, Vogelbaum MA. CODEL: phase III study of RT, RT?+ TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. Neuro Oncol. 2021 03 25; 23(3):457-467. PMID: 32678879; PMCID: PMC7992874.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    33. De Witt Hamer PC, Klein M, Hervey-Jumper SL, Wefel JS, Berger MS. Functional Outcomes and Health-Related Quality of Life Following Glioma Surgery. Neurosurgery. 2021 03 15; 88(4):720-732. PMID: 33517431; PMCID: PMC7955971.
      Citations: 7     Fields:    Translation:Humans
    34. Mrugala MM, Ostrom QT, Pressley SM, Taylor JW, Thomas AA, Wefel JS, Coven SL, Acquaye AA, Haynes C, Agnihotri S, Lim M, Peters KB, Sulman EP, Salcido JT, Butowski NA, Hervey-Jumper S, Mansouri A, Oliver KR, Porter AB, Nassiri F, Schiff D, Dunbar EM, Hegi ME, Armstrong TS, van den Bent MJ, Chang SM, Zadeh G, Chheda MG. The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab035. PMID: 34007966; PMCID: PMC7928618.
      Citations: 1     
    35. Noll KR, Chen HS, Wefel JS, Kumar VA, Hou P, Ferguson SD, Rao G, Johnson JM, Schomer DF, Suki D, Prabhu SS, Liu HL. Alterations in Functional Connectomics Associated With Neurocognitive Changes Following Glioma Resection. Neurosurgery. 2021 02 16; 88(3):544-551. PMID: 33080024; PMCID: PMC7884148.
      Citations: 3     Fields:    Translation:Humans
    36. Noll KR, Walbert T, Wefel JS. Impaired neurocognitive function in glioma patients: from pathophysiology to novel intervention strategies. Curr Opin Neurol. 2020 12; 33(6):716-722. PMID: 33009006.
      Citations: 1     Fields:    Translation:Humans
    37. Quirarte JA, Kumar VA, Liu HL, Noll KR, Wefel JS, Lang FF. Language supplementary motor area syndrome correlated with dynamic changes in perioperative task-based functional MRI activations: case report. J Neurosurg. 2020 06 05; 134(6):1738-1742. PMID: 32502992.
      Citations:    Fields:    Translation:Humans
    38. Wefel JS. Improving access and standard of care for all. Neurooncol Pract. 2020 Jun; 7(3):261-262. PMID: 32537174; PMCID: PMC7274185.
    39. Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS, Bovi JA, Robinson C, Konski A, Khuntia D, Grosshans D, Benzinger TLS, Bruner D, Gilbert MR, Kundapur V, Devisetty K, Shah S, Usuki K, Anderson BM, Stea B, Yoon H, Li J, Laack NN, Kruser TJ, Chmura SJ, Shi W, Deshmukh S, Mehta MP, Kachnic LA, for NRG Oncology, Roberge D. Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. J Clin Oncol. 2020 04 01; 38(10):1019-1029. PMID: 32058845; PMCID: PMC7106984.
      Citations: 127     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    40. Kumthekar P, Tang SC, Brenner AJ, Kesari S, Piccioni DE, Anders C, Carrillo J, Chalasani P, Kabos P, Puhalla S, Tkaczuk K, Garcia AA, Ahluwalia MS, Wefel JS, Lakhani N, Ibrahim N. ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clin Cancer Res. 2020 06 15; 26(12):2789-2799. PMID: 31969331.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    41. Zeng Y, Dong J, Huang M, Zhang JE, Zhang X, Xie M, Wefel JS. Nonpharmacological interventions for cancer-related cognitive impairment in adult cancer patients: A network meta-analysis. Int J Nurs Stud. 2020 Apr; 104:103514. PMID: 32004776.
      Citations: 5     Fields:    Translation:Humans
    42. Ryan C, Wefel JS, Morgans AK. A review of prostate cancer treatment impact on the CNS and cognitive function. Prostate Cancer Prostatic Dis. 2020 06; 23(2):207-219. PMID: 31844181; PMCID: PMC7237350.
      Citations: 19     Fields:    Translation:Humans
    43. Wefel JS. Opportunities to enhance our management, outcomes, and interventions for patients with CNS malignancy. Neurooncol Pract. 2019 Jul; 6(4):247-248. PMID: 31386055; PMCID: PMC6660814.
    44. Noll KR, Bradshaw ME, Parsons MW, Dawson EL, Rexer J, Wefel JS. Monitoring of Neurocognitive Function in the Care of Patients with Brain Tumors. Curr Treat Options Neurol. 2019 Jun 28; 21(7):33. PMID: 31250277.
      Citations: 7     
    45. van Lonkhuizen PJC, Klaver KM, Wefel JS, Sitskoorn MM, Schagen SB, Gehring K. Interventions for cognitive problems in adults with brain cancer: A narrative review. Eur J Cancer Care (Engl). 2019 May; 28(3):e13088. PMID: 31090162; PMCID: PMC9285967.
      Citations: 16     Fields:    Translation:HumansAnimals
    46. Estevis E, Noll KR, Bradshaw ME, Wefel JS. Driver safety in patients with primary brain tumors. Neurooncol Pract. 2019 Dec; 6(6):490-498. PMID: 31832220; PMCID: PMC6899044.
    47. Noll KR, Sullaway CM, Wefel JS. Depressive symptoms and executive function in relation to survival in patients with glioblastoma. J Neurooncol. 2019 Mar; 142(1):183-191. PMID: 30680509.
      Citations: 12     Fields:    Translation:Humans
    48. Hall WA, Pugh SL, Wefel JS, Armstrong TS, Gilbert MR, Brachman DG, Werner-Wasik M, Wendland MM, Brown PD, Chao ST, Roof KS, Robins HI, Mehta MP, Curran WJ, Movsas B. Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes. Neurosurgery. 2019 01 01; 84(1):66-76. PMID: 29618054; PMCID: PMC6500905.
      Citations: 2     Fields:    Translation:Humans
    49. Laack NN, Pugh SL, Brown PD, Fox S, Wefel JS, Meyers C, Choucair A, Khuntia D, Suh JH, Roberge D, Wendland MM, Bruner D. The association of health-related quality of life and cognitive function in patients receiving memantine for the prevention of cognitive dysfunction during whole-brain radiotherapy. Neurooncol Pract. 2019 Jul; 6(4):274-282. PMID: 31386073; PMCID: PMC6660822.
      Citations: 4     
    50. Harrison RA, Kesler SR, Johnson JM, Penas-Prado M, Sullaway CM, Wefel JS. Neurocognitive dysfunction in adult cerebellar medulloblastoma. Psychooncology. 2019 01; 28(1):131-138. PMID: 30315720.
      Citations: 7     Fields:    Translation:Humans
    51. Wefel JS. Food for thought: patient outcomes, diagnostic challenges, and therapeutic possibilities. Neurooncol Pract. 2018 Nov; 5(4):203. PMID: 31385963; PMCID: PMC6656306.
    52. Harrison RA, Wefel JS. Neurocognitive Function in Adult Cancer Patients. Neurol Clin. 2018 08; 36(3):653-674. PMID: 30072075.
      Citations: 6     Fields:    Translation:Humans
    53. Hardy SJ, Krull KR, Wefel JS, Janelsins M. Cognitive Changes in Cancer Survivors. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:795-806. PMID: 30231372.
      Citations: 22     Fields:    Translation:Humans
    54. Noll KR, Bradshaw ME, Rexer J, Wefel JS. Neuropsychological Practice in the Oncology Setting. Arch Clin Neuropsychol. 2018 May 01; 33(3):344-353. PMID: 29718081; PMCID: PMC5920294.
      Citations: 5     Fields:    Translation:Humans
    55. Wefel JS. Patient-centered care in neuro-oncology. Neurooncol Pract. 2018 Mar; 5(1):1. PMID: 31385979; PMCID: PMC6655364.
    56. Camidge DR, Lee EQ, Lin NU, Margolin K, Ahluwalia MS, Bendszus M, Chang SM, Dancey J, de Vries EGE, Harris GJ, Hodi FS, Lassman AB, Macdonald DR, Peereboom DM, Schiff D, Soffietti R, van den Bent MJ, Wefel JS, Wen PY. Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol. 2018 01; 19(1):e20-e32. PMID: 29304358.
      Citations: 31     Fields:    Translation:Humans
    57. Alexander BM, Brown PD, Ahluwalia MS, Aoyama H, Chang SM, Gaspar LE, Kalkanis SN, Macdonald DR, Mehta MP, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Lee EQ, Wen PY, Response Assessment in Neuro-Oncology (RANO) group, Baumert BG. Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol. 2018 01; 19(1):e33-e42. PMID: 29304360.
      Citations: 11     Fields:    Translation:Humans
    58. Wefel JS, Parsons MW, Gondi V, Brown PD. Neurocognitive aspects of brain metastasis. Handb Clin Neurol. 2018; 149:155-165. PMID: 29307352.
      Citations: 8     Fields:    Translation:Humans
    59. Brown PD, Ahluwalia MS, Khan OH, Asher AL, Wefel JS, Gondi V. Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution? J Clin Oncol. 2018 02 10; 36(5):483-491. PMID: 29272161; PMCID: PMC6075843.
      Citations: 57     Fields:    Translation:Humans
    60. Wefel JS. Choosing clinical trial endpoints, aggregating data, and making clinical decisions. Neurooncol Pract. 2017 Dec; 4(4):199-200. PMID: 31385989; PMCID: PMC6655419.
    61. Moruno-Manchon JF, Uzor NE, Kesler SR, Wefel JS, Townley DM, Nagaraja AS, Pradeep S, Mangala LS, Sood AK, Tsvetkov AS. Peroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy. Mol Cell Neurosci. 2018 01; 86:65-71. PMID: 29180229; PMCID: PMC6996272.
      Citations: 16     Fields:    Translation:AnimalsCells
    62. Noll KR, Bradshaw ME, Weinberg JS, Wefel JS. Neurocognitive functioning is associated with functional independence in newly diagnosed patients with temporal lobe glioma. Neurooncol Pract. 2018 Aug; 5(3):184-193. PMID: 30094046; PMCID: PMC6075221.
      Citations: 11     
    63. Schagen SB, Wefel JS. Post-traumatic Stress as the Primary Cause for Cognitive Decline-Not the Whole Story, and Perhaps No Story at All. J Natl Cancer Inst. 2017 10 01; 109(10). PMID: 28521366.
      Citations:    Fields:    Translation:Humans
    64. Salek KE, Hassan IS, Kotrotsou A, Abrol S, Faro SH, Mohamed FB, Zinn PO, Wei W, Li N, Kumar AJ, Weinberg JS, Wefel JS, Kesler SR, Liu HA, Hou P, Stafford RJ, Prabhu S, Sawaya R, Colen RR. Silent Sentence Completion Shows Superiority Localizing Wernicke's Area and Activation Patterns of Distinct Language Paradigms Correlate with Genomics: Prospective Study. Sci Rep. 2017 09 21; 7(1):12054. PMID: 28935966; PMCID: PMC5608896.
      Citations: 4     Fields:    Translation:Humans
    65. Armstrong TS, Vera E, Zhou R, Acquaye AA, Sullaway CM, Berger AM, Breton G, Mahajan A, Wefel JS, Gilbert MR, Bondy M, Scheurer ME. Association of genetic variants with fatigue in patients with malignant glioma. Neurooncol Pract. 2018 May; 5(2):122-128. PMID: 31386001; PMCID: PMC6655500.
      Citations: 4     
    66. Hansen CC, Smith JB, Mohamed ASR, Mulcahy CF, Wefel JS, Hutcheson KA, Chrane K, Phan J, Frank SJ, Garden AS, Smith BD, Eichelberger H, Anderson C, McCoy C, Horiates M, Patrick C, Floris S, French C, Beadle BM, Morrison WH, Su SY, Lewis CM, Kupferman ME, Johnson JM, Skinner HD, Lai SY, Hanna EY, Rosenthal DI, Fuller CD, Gunn GB, MD Anderson Head and Neck Cancer Symptom Working Group. Cognitive function and patient-reported memory problems after radiotherapy for cancers at the skull base: A cross-sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventory-Head and Neck Module. Head Neck. 2017 10; 39(10):2048-2056. PMID: 28763137; PMCID: PMC6082378.
      Citations: 3     Fields:    Translation:HumansPHPublic Health
    67. Wefel JS, Noll KR, Rao G, Cahill DP. Reply to Freyschlag et al. Neuro Oncol. 2017 04 01; 19(4):598-599. PMID: 28339696; PMCID: PMC5464303.
      Citations:    Fields:    Translation:Humans
    68. Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, Chen A, Grossman S, Prados M, Wen PY. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. J Neurooncol. 2017 03; 132(1):181-188. PMID: 28116649; PMCID: PMC5588922.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    69. Moruno-Manchon JF, Uzor NE, Kesler SR, Wefel JS, Townley DM, Nagaraja AS, Pradeep S, Mangala LS, Sood AK, Tsvetkov AS. TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin. Aging (Albany NY). 2016 12 16; 8(12):3507-3519. PMID: 27992857; PMCID: PMC5270683.
      Citations: 23     Fields:    Translation:AnimalsCells
    70. Kesler SR, Noll K, Cahill DP, Rao G, Wefel JS. The effect of IDH1 mutation on the structural connectome in malignant astrocytoma. J Neurooncol. 2017 02; 131(3):565-574. PMID: 27848136; PMCID: PMC5377918.
      Citations: 29     Fields:    Translation:Humans
    71. Wefel JS. Neuro-Oncology Practice: Learning from our past to guide our future. Neurooncol Pract. 2016 Dec; 3(4):209-210. PMID: 31386053; PMCID: PMC6657398.
    72. Wefel JS, Noll KR, Rao G, Cahill DP. Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection. Neuro Oncol. 2016 12; 18(12):1656-1663. PMID: 27576872; PMCID: PMC5744240.
      Citations: 38     Fields:    Translation:Humans
    73. Manchon JF, Dabaghian Y, Uzor NE, Kesler SR, Wefel JS, Tsvetkov AS. Levetiracetam mitigates doxorubicin-induced DNA and synaptic damage in neurons. Sci Rep. 2016 05 11; 6:25705. PMID: 27168474; PMCID: PMC4863375.
      Citations: 21     Fields:    Translation:AnimalsCells
    74. Day J, Yust-Katz S, Cachia D, Wefel J, Katz LH, Tremont I, Bulbeck H, Armstrong T, Rooney AG. Interventions for the management of fatigue in adults with a primary brain tumour. Cochrane Database Syst Rev. 2016 Apr 13; 4:CD011376. PMID: 27074263; PMCID: PMC8719625.
      Citations: 16     Fields:    Translation:Humans
    75. Noll KR, Ziu M, Weinberg JS, Wefel JS. Neurocognitive functioning in patients with glioma of the left and right temporal lobes. J Neurooncol. 2016 06; 128(2):323-31. PMID: 27022915; PMCID: PMC4884162.
      Citations: 23     Fields:    Translation:Humans
    76. Wefel JS, Noll KR, Scheurer ME. Neurocognitive functioning and genetic variation in patients with primary brain tumours. Lancet Oncol. 2016 Mar; 17(3):e97-e108. PMID: 26972863; PMCID: PMC5215729.
      Citations: 22     Fields:    Translation:Humans
    77. Blakeley JO, Coons SJ, Corboy JR, Kline Leidy N, Mendoza TR, Wefel JS. Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations. Neuro Oncol. 2016 Mar; 18 Suppl 2:ii13-ii20. PMID: 26989128; PMCID: PMC4795998.
      Citations: 14     Fields:    Translation:HumansAnimals
    78. Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2016 Mar 20; 34(9):945-52. PMID: 26834058; PMCID: PMC5070554.
      Citations: 64     Fields:    Translation:HumansCTClinical Trials
    79. Noll KR, Bradshaw ME, Weinberg JS, Wefel JS. Relationships between neurocognitive functioning, mood, and quality of life in patients with temporal lobe glioma. Psychooncology. 2017 05; 26(5):617-624. PMID: 26677053; PMCID: PMC4995149.
      Citations: 19     Fields:    Translation:Humans
    80. Noll KR, Weinberg JS, Ziu M, Wefel JS. Verbal Learning Processes in Patients with Glioma of the Left and Right Temporal Lobes. Arch Clin Neuropsychol. 2016 Feb; 31(1):37-46. PMID: 26537777; PMCID: PMC4718189.
      Citations: 2     Fields:    Translation:Humans
    81. Wefel JS. Cancer neurology, neuro-oncology, and clinical decision making. Neurooncol Pract. 2015 Dec; 2(4):159-160. PMID: 31386062; PMCID: PMC6664619.
    82. Weinberg JS, Ziu M, Benveniste RJ, Suki D, Wefel JS, Noll KR. Neurocognitive Changes Associated With Surgical Resection of Left and Right Temporal Lobe Glioma. Neurosurgery. 2015 Nov; 77(5):777-85. PMID: 26317672; PMCID: PMC4831270.
      Citations: 17     Fields:    Translation:Humans
    83. Noll KR, Wefel JS. Response to "From histology to neurocognition: the influence of tumor grade in glioma of the left temporal lobe on neurocognitive function". Neuro Oncol. 2015 Oct; 17(10):1421-2. PMID: 26395063; PMCID: PMC4578593.
      Citations:    Fields:    Translation:Humans
    84. De Ruiter MB, Small BJ, Dubois M, Schagen SB, Ahles TA, Wefel JS, Vardy JL, Joly F, Giffard B, Rigal O, LeFel J, Pancr? V, Lange M, Castel H. Impact of Cancer and Its Treatments on Cognitive Function: Advances in Research From the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012. J Pain Symptom Manage. 2015 Dec; 50(6):830-41. PMID: 26344551.
      Citations: 50     Fields:    Translation:HumansAnimals
    85. Liu Y, Zhou R, Sulman EP, Scheurer ME, Boehling N, Armstrong GN, Tsavachidis S, Liang FW, Etzel CJ, Conrad CA, Gilbert MR, Armstrong TS, Bondy ML, Wefel JS. Genetic Modulation of Neurocognitive Function in Glioma Patients. Clin Cancer Res. 2015 Jul 15; 21(14):3340-6. PMID: 25904748; PMCID: PMC4506227.
      Citations: 19     Fields:    Translation:Humans
    86. Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin. 2015 Mar; 65(2):123-38. PMID: 25483452; PMCID: PMC4355212.
      Citations: 152     Fields:    Translation:HumansAnimals
    87. Wefel JS. Neuro-Oncology Practice: Time Flies When You Are Having Fun! Neurooncol Pract. 2014 Dec; 1(4):143-144. PMID: 26034625; PMCID: PMC4369715.
    88. Noll KR, Sullaway C, Ziu M, Weinberg JS, Wefel JS. Relationships between tumor grade and neurocognitive functioning in patients with glioma of the left temporal lobe prior to surgical resection. Neuro Oncol. 2015 Apr; 17(4):580-7. PMID: 25227126; PMCID: PMC4483071.
      Citations: 58     Fields:    Translation:Humans
    89. Gilbert MR, Dignam J, Pugh S, Armstrong TS, Wefel JS, Aldape K, Stupp R, Hegi M, Won M, Curran WJ, Mehta MP. Reply to M.C. Chamberlain. J Clin Oncol. 2014 May 20; 32(15):1634-5. PMID: 24752060; PMCID: PMC4026583.
      Citations:    Fields:    Translation:Humans
    90. Wefel JS, Kornet RL, Schagen SB. Systemically treated breast cancer patients and controls: an evaluation of the presence of noncredible performance. J Int Neuropsychol Soc. 2014 Apr; 20(4):357-69. PMID: 24607070.
      Citations: 1     Fields:    Translation:Humans
    91. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ, Mehta MP. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20; 370(8):699-708. PMID: 24552317; PMCID: PMC4201043.
      Citations: 1076     Fields:    Translation:HumansCTClinical Trials
    92. Wefel JS, Vidrine DJ, Marani SK, Swartz RJ, Veramonti TL, Meyers CA, Hoekstra HJ, Hoekstra-Weebers JE, Gritz ER. A prospective study of cognitive function in men with non-seminomatous germ cell tumors. Psychooncology. 2014 Jun; 23(6):626-33. PMID: 24339329; PMCID: PMC4066616.
      Citations: 22     Fields:    Translation:Humans
    93. Kesler SR, Watson C, Koovakkattu D, Lee C, O'Hara R, Mahaffey ML, Wefel JS. Elevated prefrontal myo-inositol and choline following breast cancer chemotherapy. Brain Imaging Behav. 2013 Dec; 7(4):501-10. PMID: 23536015; PMCID: PMC3731420.
      Citations: 18     Fields:    Translation:HumansCells
    94. Armstrong TS, Wefel JS, Wang M, Gilbert MR, Won M, Bottomley A, Mendoza TR, Coens C, Werner-Wasik M, Brachman DG, Choucair AK, Mehta M. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol. 2013 Nov 10; 31(32):4076-84. PMID: 24101048; PMCID: PMC3816957.
      Citations: 66     Fields:    Translation:HumansCTClinical Trials
    95. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ, Mehta MP. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013 Nov 10; 31(32):4085-91. PMID: 24101040; PMCID: PMC3816958.
      Citations: 384     Fields:    Translation:HumansCellsCTClinical Trials
    96. Jones D, Vichaya EG, Wang XS, Sailors MH, Cleeland CS, Wefel JS. Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. Cancer. 2013 Dec 01; 119(23):4188-95. PMID: 24105672; PMCID: PMC3834212.
      Citations: 22     Fields:    Translation:Humans
    97. Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Camidge DR, Chang SM, Dancey J, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Lamborn KR, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Wen PY, Response Assessment in Neuro-Oncology (RANO) group. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol. 2013 Sep; 14(10):e396-406. PMID: 23993384.
      Citations: 48     Fields:    Translation:Humans
    98. Schagen SB, Wefel JS. Chemotherapy-related changes in cognitive functioning. EJC Suppl. 2013 Sep; 11(2):225-32. PMID: 26217131; PMCID: PMC4041313.
      Citations: 14     
    99. Lin NU, Wefel JS, Lee EQ, Schiff D, van den Bent MJ, Soffietti R, Suh JH, Vogelbaum MA, Mehta MP, Dancey J, Linskey ME, Camidge DR, Aoyama H, Brown PD, Chang SM, Kalkanis SN, Barani IJ, Baumert BG, Gaspar LE, Hodi FS, Macdonald DR, Wen PY, Response Assessment in Neuro-Oncology (RANO) group. Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol. 2013 Sep; 14(10):e407-16. PMID: 23993385.
      Citations: 52     Fields:    Translation:Humans
    100. Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, Choucair A, Fox S, Suh JH, Roberge D, Kavadi V, Bentzen SM, Mehta MP, Watkins-Bruner D, Radiation Therapy Oncology Group (RTOG). Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013 Oct; 15(10):1429-37. PMID: 23956241; PMCID: PMC3779047.
      Citations: 258     Fields:    Translation:Humans
    101. Welsh JW, McGovern SL, Wefel JS, Komaki R, Brown PD, Soh HE. Reply to v.R. Bhatt et Al and m.C. Chamberlain. J Clin Oncol. 2013 Sep 01; 31(25):3165-6. PMID: 23943829.
      Citations:    Fields:    Translation:Humans
    102. Kesler SR, Wefel JS, Hosseini SM, Cheung M, Watson CL, Hoeft F. Default mode network connectivity distinguishes chemotherapy-treated breast cancer survivors from controls. Proc Natl Acad Sci U S A. 2013 Jul 09; 110(28):11600-5. PMID: 23798392; PMCID: PMC3710809.
      Citations: 60     Fields:    Translation:Humans
    103. Johnson DR, Wefel JS. Relationship between cognitive function and prognosis in glioblastoma. CNS Oncol. 2013 Mar; 2(2):195-201. PMID: 25057978; PMCID: PMC6169490.
      Citations: 10     Fields:    Translation:Humans
    104. Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, Chen SS, Holt J, Liao Z, Brown P, Sulman E, Heymach JV, Kim ES, Stea B. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013 Mar 01; 31(7):895-902. PMID: 23341526; PMCID: PMC3577951.
      Citations: 177     Fields:    Translation:HumansCTClinical Trials
    105. Wefel JS, Schagen SB. Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep. 2012 Jun; 12(3):267-75. PMID: 22453825.
      Citations: 118     Fields:    Translation:HumansAnimals
    106. Johnson DR, Sawyer AM, Meyers CA, O'Neill BP, Wefel JS. Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma. Neuro Oncol. 2012 Jun; 14(6):808-16. PMID: 22508762; PMCID: PMC3367851.
      Citations: 40     Fields:    Translation:Humans
    107. Armstrong TS, Wefel JS, Gning I, Acquaye A, Vera-Bolanos E, Gilbert MR, Cleeland CS, Mendoza T. Congruence of primary brain tumor patient and caregiver symptom report. Cancer. 2012 Oct 15; 118(20):5026-37. PMID: 22415423.
      Citations: 14     Fields:    Translation:Humans
    108. Schapiro R, Ferson D, Prabhu SS, Tummula S, Wefel J, Rao G. A technique for mapping cortical areas associated with speech arrest. Stereotact Funct Neurosurg. 2012; 90(2):118-23. PMID: 22398728.
      Citations: 2     Fields:    Translation:Humans
    109. Wu AS, Witgert ME, Lang FF, Xiao L, Bekele BN, Meyers CA, Ferson D, Wefel JS. Neurocognitive function before and after surgery for insular gliomas. J Neurosurg. 2011 Dec; 115(6):1115-25. PMID: 21905800.
      Citations: 32     Fields:    Translation:Humans
    110. Wefel JS, Cloughesy T, Zazzali JL, Zheng M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Jun; 13(6):660-8. PMID: 21558074; PMCID: PMC3107095.
      Citations: 49     Fields:    Translation:HumansCTClinical Trials
    111. Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Grewal J, Prabhu S, Loghin M, Gilbert MR, Jackson EF. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2011 Apr 01; 79(5):1487-95. PMID: 20399573; PMCID: PMC2908725.
      Citations: 241     Fields:    Translation:HumansPHPublic Health
    112. Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011 Jul; 12(7):703-8. PMID: 21354373.
      Citations: 293     Fields:    Translation:Humans
    113. Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol. 2011 Mar; 13(3):353-61. PMID: 21310734; PMCID: PMC3064608.
      Citations: 52     Fields:    Translation:Humans
    114. Wefel JS, Vidrine DJ, Veramonti TL, Meyers CA, Marani SK, Hoekstra HJ, Hoekstra-Weebers JE, Shahani L, Gritz ER. Cognitive impairment in men with testicular cancer prior to adjuvant therapy. Cancer. 2011 Jan 01; 117(1):190-6. PMID: 20737560; PMCID: PMC6691495.
      Citations: 26     Fields:    Translation:Humans
    115. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010 Jul 15; 116(14):3348-56. PMID: 20564075.
      Citations: 166     Fields:    Translation:HumansCTClinical Trials
    116. Perrier ND, Balachandran D, Wefel JS, Jimenez C, Busaidy N, Morris GS, Dong W, Jackson E, Weaver S, Gantela S, Evans DB, Grubbs EG, Lee JE. Prospective, randomized, controlled trial of parathyroidectomy versus observation in patients with "asymptomatic" primary hyperparathyroidism. Surgery. 2009 Dec; 146(6):1116-22. PMID: 19879613.
      Citations: 20     Fields:    Translation:Humans
    117. Benge JF, Perrier ND, Massman PJ, Meyers CA, Kayl AE, Wefel JS. Cognitive and affective sequelae of primary hyperparathyroidism and early response to parathyroidectomy. J Int Neuropsychol Soc. 2009 Nov; 15(6):1002-11. PMID: 19807940.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    118. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009 Nov; 10(11):1037-44. PMID: 19801201.
      Citations: 802     Fields:    Translation:HumansPHPublic Health
    119. Friedman MA, Fernandez M, Wefel JS, Myszka KA, Champlin RE, Meyers CA. Course of cognitive decline in hematopoietic stem cell transplantation: a within-subjects design. Arch Clin Neuropsychol. 2009 Nov; 24(7):689-98. PMID: 19767298.
      Citations: 27     Fields:    Translation:Humans
    120. Monje M, Wefel J, Meyers C, Dietrich J. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist. 2008 Dec; 13(12):1285-95. PMID: 19019972.
      Citations: 100     Fields:    Translation:HumansCells
    121. Wefel JS, Witgert ME, Meyers CA. Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. Neuropsychol Rev. 2008 Jun; 18(2):121-31. PMID: 18415683.
      Citations: 40     Fields:    Translation:HumansAnimals
    122. Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, Wefel JS, Gilbert MR, Ictech S, Hunter KU, Forman AD, Puduvalli VK, Colman H, Hess KR, Yung WK. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol. 2008 Apr; 10(2):208-15. PMID: 18316473; PMCID: PMC2613823.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    123. Mittendorf EA, Wefel JS, Meyers CA, Doherty D, Shapiro SE, Lee JE, Evans DB, Perrier ND. Improvement of sleep disturbance and neurocognitive function after parathyroidectomy in patients with primary hyperparathyroidism. Endocr Pract. 2007 Jul-Aug; 13(4):338-44. PMID: 17669708.
      Citations: 10     Fields:    Translation:Humans
    124. Chang EL, Wefel JS, Maor MH, Hassenbusch SJ, Mahajan A, Lang FF, Woo SY, Mathews LA, Allen PK, Shiu AS, Meyers CA. A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery. 2007 Feb; 60(2):277-83; discussion 283-4. PMID: 17290178.
      Citations: 42     Fields:    Translation:Humans
    125. Kayl AE, Wefel JS, Meyers CA. Chemotherapy and cognition: effects, potential mechanisms, and management. Am J Ther. 2006 Jul-Aug; 13(4):362-9. PMID: 16858172.
      Citations: 5     Fields:    Translation:Humans
    126. Heflin LH, Meyerowitz BE, Hall P, Lichtenstein P, Johansson B, Pedersen NL, Gatz M. Re: Cancer as a risk factor for dementia: a house built on shifting sand. J Natl Cancer Inst. 2005 Oct 19; 97(20):1550-1; author reply 1551-2. PMID: 16234571.
      Citations: 1     Fields:    Translation:Humans
    127. Wefel JS, Meyers CA. Cancer as a risk factor for dementia: a house built on shifting sand. J Natl Cancer Inst. 2005 Jun 01; 97(11):788-9. PMID: 15928294.
      Citations: 6     Fields:    Translation:Humans
    128. Maruff P, Falleti MG, Collie A. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma. Results of a prospective, randomized, longitudinal trial. Cancer. 2004 Nov 01; 101(9):2143-4; author reply 2144-5. PMID: 15382092.
      Citations: 2     Fields:    Translation:Humans
    129. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. 'Chemobrain' in breast carcinoma?: a prologue. Cancer. 2004 Aug 01; 101(3):466-75. PMID: 15274059.
      Citations: 106     Fields:    Translation:Humans
    130. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004 Jun 01; 100(11):2292-9. PMID: 15160331.
      Citations: 206     Fields:    Translation:HumansCTClinical Trials
    131. Atchison TB, Sander AM, Struchen MA, High WM, Roebuck TM, Contant CF, Wefel JS, Novack TA, Sherer M. Relationship between neuropsychological test performance and productivity at 1-year following traumatic brain injury. Clin Neuropsychol. 2004 May; 18(2):249-65. PMID: 15587672.
      Citations: 4     Fields:    Translation:Humans
    132. Meyers CA, Wefel JS. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol. 2003 Oct 01; 21(19):3557-8. PMID: 12913103.
      Citations: 90     Fields:    Translation:HumansPHPublic Health
    133. Neurocognitive effects.
    134. Cognitive complaints after breast cancer treatments. Breast Diseases. 25:92-93.
    135. Whole-brain irradiation for patients with brain metastases. The Lancet Oncology. 11:223.
    136. Relationships between neurocognitive functioning, mood, and quality of life in patients with temporal lobe glioma. Psycho-Oncology.
    137. Chemotherapy-related changes in cognitive functioning. European Journal of Cancer, Supplement. 11:225-232.
    138. Monitoring and optimising cognitive function in cancer patients. European Journal of Cancer, Supplement. 12:29-40.
    139. Verbal Learning Processes in Patients with Glioma of the Left and Right Temporal Lobes. Archives of Clinical Neuropsychology. 31:37-46.
    140. Catechol-o-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Breast Diseases. 22:411-412.
    141. Impact of Cancer and Its Treatments on Cognitive Function. Journal of Pain and Symptom Management. 50:830-841.
    142. Neurocognitive functioning in patients with glioma of the left and right temporal lobes. Journal of Neuro-Oncology. 1-9.
    143. Erratum. International Journal of Radiation Oncology Biology Physics. 84.
    144. Neuropsychological assessment of adults with cancer. 44-55.
    145. Reply to acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 117:1103.
    146. Cognitive dysfunction related to chemotherapy and biological response modifiers. 97-114.
    147. Clinical outcome assessment in malignant glioma trials. Neuro-Oncology. 18:ii13-ii20.
    148. The effect of IDH1 mutation on the structural connectome in malignant astrocytoma. Journal of Neuro-Oncology. 1-10.
    149. Neurocognitive changes associated with surgical resection of left and right temporal lobe glioma. Neurosurgery. 77:777-785.
    150. A randomized trial of bevacizumab for newly diagnosed glioblastoma. New England Journal of Medicine. 370:699-708.
    151. Erratum. Current Neurology and Neuroscience Reports. 12:340.
    152. Genetic modulation of neurocognitive function in glioma patients. Clinical Cancer Research. 21:3340-3346.
    153. Levetiracetam mitigates doxorubicin-induced DNA and synaptic damage in neurons. Scientific Reports. 6.
    154. Neurocognitive testing in clinical trials. 320-328.
    WEFEL's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (304)
    Co-Authors (93)
    Similar People (60)
    Same Department Expand Description